Understanding CMS’s GLOBE Model in 2026: What Pharma and Biotech Need to Know
December 2025 marked a pivotal moment in U.S. drug pricing policy. The Global Benchmark for
December 2025 marked a pivotal moment in U.S. drug pricing policy. The Global Benchmark for
Most Favoured Nation (MFN) pricing policies are increasingly shaping global pharmaceutical launch, pricing, and access
What began as “Most Favored Nation” (MFN) concepts has now materialized into concrete policy mechanisms.
The EU Health Technology Assessment Regulation (HTAR) represents one of the most significant shifts in
In 2023, U.S. retail prescription drug market value grew 11.4% to $449.7B, about 9% of
The Italian Medicines Agency has published their annual AIFA Activity Report in 2025, outlining the